Research Analysts’ Recent Ratings Changes for Scholar Rock (SRRK)

Scholar Rock (NASDAQ: SRRK) has recently received a number of price target changes and ratings updates:

• 9/21/2026 – Scholar Rock had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $70.00 price target on the stock.
• 9/21/2026 – Scholar Rock had its price target raised by JPMorgan Chase & Co. from $63.00 to $70.00. They now have an “overweight” rating on the stock.
• 9/15/2026 – Scholar Rock had its “buy” rating reaffirmed by UBS Group AG.
• 9/15/2026 – Scholar Rock had its “outperform” rating reaffirmed by Evercore Inc. They now have a $72.00 price target on the stock.
• 9/15/2026 – Scholar Rock had its “outperform” rating reaffirmed by Wedbush. They now have a $64.00 price target on the stock.
• 9/15/2026 – Scholar Rock had its price target raised by Piper Sandler from $60.00 to $75.00. They now have an “overweight” rating on the stock.
• 9/15/2026 – Scholar Rock had its price target raised by HC Wainwright from $65.00 to $70.00. They now have a “buy” rating on the stock.
• 9/15/2026 – Scholar Rock was downgraded by Barclays PLC from “overweight” to “cautious”.
• 9/14/2026 – Scholar Rock had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $58.00 price target on the stock, up from $55.00.
• 9/14/2026 – Scholar Rock had its price target raised by Jefferies Financial Group Inc. from $57.00 to $65.00. They now have a “buy” rating on the stock.
• 9/14/2026 – Scholar Rock had its “buy” rating reaffirmed by TD Cowen.
• 9/14/2026 – Scholar Rock had its price target raised by BMO Capital Markets from $76.00 to $84.00. They now have an “outperform” rating on the stock.
• 9/14/2026 – Scholar Rock had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $76.00 price target on the stock, up from $55.00.
• 9/14/2026 – Scholar Rock had its price target raised by Raymond James Financial, Inc. from $65.00 to $72.00. They now have a “strong-buy” rating on the stock.
• 9/14/2026 – Scholar Rock had its price target raised by Citigroup Inc. from $60.00 to $74.00. They now have a “buy” rating on the stock.
• 9/14/2026 – Scholar Rock was upgraded by Jefferies Financial Group Inc. to “strong-buy”.
• 9/14/2026 – Scholar Rock had its “outperform” rating reaffirmed by Wedbush. They now have a $64.00 price target on the stock.
• 9/10/2026 – Scholar Rock had its price target raised by BMO Capital Markets from $76.00 to $84.00. They now have an “outperform” rating on the stock.
• 9/8/2026 – Scholar Rock was downgraded by HC Wainwright from “buy” to “neutral”.
• 9/8/2026 – Scholar Rock had its “buy” rating reaffirmed by HC Wainwright. They now have a $65.00 price target on the stock.
• 8/21/2026 – Scholar Rock had its “outperform” rating reaffirmed by Wedbush. They now have a $64.00 price target on the stock.
• 8/13/2026 – Scholar Rock had its price target raised by JPMorgan Chase & Co. from $56.00 to $63.00. They now have an “overweight” rating on the stock.
• 8/10/2026 – Scholar Rock had its “buy” rating reaffirmed by HC Wainwright. They now have a $65.00 price target on the stock.
• 8/10/2026 – Scholar Rock had its “outperform” rating reaffirmed by Wedbush. They now have a $58.00 price target on the stock.
• 8/7/2026 – Scholar Rock had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $76.00 price target on the stock.
• 8/7/2026 – Scholar Rock had its price target raised by Citigroup Inc. from $58.00 to $60.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other news, Director Michael Gilman sold 2,544 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $53.87, for a total value of $137,045.28. Following the transaction, the director directly owned 59,511 shares of the company’s stock, valued at $3,205,857.57. The trade was a 4.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Katie Peng sold 5,446 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total value of $293,430.48. Following the sale, the director owned 34,301 shares in the company, valued at approximately $1,848,137.88. This trade represents a 13.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 17,149 shares of company stock valued at $923,108 in the last ninety days. 10.30% of the stock is owned by corporate insiders.

Scholar Rock, Inc is a biopharmaceutical company focused on developing medicines that selectively target growth factors in their latent forms. The company’s approach is designed to modulate the activation of growth factors in specific tissues, with the goal of addressing diseases in which these biological pathways contribute to impaired function or abnormal tissue growth.

Scholar Rock’s lead program is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin. The company has studied apitegromab as a potential treatment for spinal muscular atrophy, a genetic neuromuscular disorder that causes progressive muscle weakness and loss of motor function.